Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415

Benzinga · 2d ago
Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $407 to $415.